Navigation Links
Ikaria® CEO Daniel Tasse Elected to PhRMA Board of Directors
Date:9/22/2011

HAMPTON, N.J., Sept. 22, 2011 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients in the hospital and ICU settings, today announced that its Chairman and CEO Daniel Tasse has been elected to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Headquartered in Washington, D.C., PhRMA represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier and more productive lives.

In addition to his membership on the 31-person board, Mr. Tasse will serve on the PhRMA Rare Disease and Emerging Company Committees.  Mr. Tasse brings to these positions an extensive track record in the healthcare industry with a wealth of knowledge and passion for critical care, in particular.

"I'm honored to join this prestigious group of industry leaders and innovators," said Mr. Tasse. "Through my new position on PhRMA's Board of Directors, I look forward to helping to move forward policies that will advance the pharmaceutical industry and continue to benefit patients during this important time for our industry and our economy."

Mr. Tasse also is a member of the Board of Directors and Health Section Governing Board of the Biotechnology Industry Organization (BIO), where he participates on the bioethics, regulatory environment and reimbursement committees.  Additionally, he is a member of the Healthcare Leadership Council and is a member of the Board of Directors of the Roundtable on Critical Care Policy.

Prior to joining Ikaria, Mr. Tasse served as General Manager of the Pharmaceutical Technologies Business Unit of Baxter International.  Earlier in his career, Mr. Tasse held a number of Senior Management positions at GlaxoSmithKline, including that of Vice President and Regional Director for AustralAsia.  He earned a B.S. in Biochemistry from the University of Montreal.

About Ikaria Inc.Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is pursuing a number of new indications with INOMAX. Ikaria's late stage pipeline is also comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1; as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit www.ikaria.com. Company Contact:Media Contacts:Samina Bari

Tiberend Strategic Advisors, Inc.Ikaria, Inc.

(212) 827-0020(908) 238-6372

Claire Sojdasamina.bari@ikaria.com

csojda@tiberend.com
'/>"/>

SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ikaria® Names New Chief Financial Officer
2. Ikaria® to Present at 31st Annual Cowen and Company Healthcare Conference
3. Ikaria® Launches Next-Generation Drug-Delivery System
4. Ikaria® to Present at 2011 Wedbush Life Sciences Management Access Conference
5. Daniel K. Spiegelman Elected to Board of Directors of Omeros
6. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
7. Governor Daniels Signs Into Law Electronic Tracking Bill
8. Daniels Jumps to No. 2 in Medical Waste Disposal Industry
9. Daniels Sharpsmart Expands U.S. Presence With New Pennsylvania Facility
10. Daniels Sharpsmart Expands U.S. Presence With New Facility in Midwest
11. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... LOS ANGELES , July 12, 2017 CarpalAID is ... without drugs, braces or surgery. Carpal tunnel syndrome affects ... tunnel syndrome at twice the rate of men. The common methods ... steroids, or mobilization with uncomfortable hand braces or gloves. ... CarpalAID is a ...
(Date:7/11/2017)... , July 11, 2017 Zymo Research Corp., also known ... that can quantify biological aging in a precise manner using the myDNAge ... Steve Horvath , a professor of human genetics and biostatistics at the ... School of Public Health , Zymo Research,s proprietary DNAge ™ technology ... ...
(Date:7/11/2017)...  The global market for liquid biopsy diagnostic and ... in 2016.  Although in early stages, the global market ... as a result of the gradual shift towards personalized ... of a significant number of new liquid biopsy tests ... biomarkers to guide treatment decisions. ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... Centurion Service Group ... Regional Account Manager for the Northeast and Florida regions. In this role, Jennifer ... obsolete medical assets. , Jennifer joins Centurion with a wealth of knowledge and ...
(Date:7/25/2017)... Texas (PRWEB) , ... July 25, 2017 , ... ... fastest growing ATM provider in the United States, today announced its partnership with ... financial institutions. , The foundation of the solution lies within Hyosung’s superior ...
(Date:7/24/2017)... ... July 24, 2017 , ... Engineers at the University of Maryland have ... same kind of electrical energy that the body uses. , In ordinary batteries ... flow of electrons out of the battery is generated by moving positive ions from ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... ... the federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response ... California Department of Health Care Services, will facilitate the development of a hub ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Every year, ... invigorating and educational conference, InstructureCon. Each annual event is coupled with a dynamic theme ... with a James Bond theme, Mission: InstructureCon 0017. , To extend their partnership ...
Breaking Medicine News(10 mins):